menu
    • menu
    [{"orgOrder":0,"company":"NephroGenex","sponsor":"Collaborative Study Group | Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Pyridoxamine dihydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"NephroGenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NephroGenex \/ Collaborative Study Group | Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"NephroGenex \/ Collaborative Study Group | Medpace, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Pyridoxamine dihydrochloride

    Menu

    Pyridoxamine dihydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NephroGenex

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            NephroGenex

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridoxamine dihydrochloride

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Collaborative Study Group | Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pyridorin in Diabetic Nephropathy

                            Details : Pyridorin is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Nephropathies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 05, 2014

                            Lead Product(s) : Pyridoxamine dihydrochloride

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Collaborative Study Group | Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth